Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD
Per US guidelines, clinicians should consider discontinuation if a patient has not lost at least 5% of initial body weight after 12 weeks on the maintenance dose
Standard blood work measures both types (left and right molecules) together, so the physician believes the Synthroid has cured hypothyroidism
Q5: Does tesamorelin require a prescription
In particular, GLP-1 receptor agonists proved to be safe and effective and are standard treatment-options for T2D now
t hiu qu tt nht, bn nn ung Glutathione trc khi n hoc khi d dy cn trng